Press release | VIB is organising its 5th Biotechday. All ages are welcome to this free event at campus Gasthuisberg in Leuven. reMYND will be presenting on the research towards the treatment of Alheimers and diabetes worldwide.
reMYND to present on Biotechdag
Measuring cognition in reMYND’s Tau animal models
reMYND’s Tau.P301L and Tau.P301S models feature progressive hyperphosphorylation of Tau with age and a strong correlation of Tau pathology with the motor phenotype.
IWT supports reMYND in developing a cure for Type 1 Diabetes
Press release | reMYND NV today announced that it has received a grant from IWT, the Flemish agency for Innovation by Science and Technology, to assess the potential of its Diabetes program in curing Type 1 Diabetes Mellitus (T1DM).
Longitudinal imaging of Tau aggregates in vivo by two-photon imaging available in reMYND’s Tau.P301S model
Two-photon imaging allows tracking the formation of Tau aggregates in the same brain-region of a live animal over the course of time. This makes it possible to study the effects of treatment longitudinally in vivo.
Transgenic mouse model of combined Abeta and tau pathology
The interplay of Abeta and Tau is considered detrimental if not crucial for disease etiology and progression of Alzheimer’s Disease.